HOME >> MEDICINE >> NEWS
Use of estrogen by postmenopausal women does not increase risk of breast cancer

CHICAGO Postmenopausal women treated with estrogen therapy for seven years did not experience an increased risk of breast cancer, according to a study in the April 12 issue of JAMA.

The Women's Health Initiative (WHI) Estrogen-Alone trial, which randomized women with prior hysterectomy to conjugated equine estrogens (CEE) or placebo, was stopped earlier than planned because of increased stroke incidence and no reduction in risk of coronary heart disease. In contrast to substantial epidemiological evidence associating exogenous (originating externally) estrogens with increased breast cancer incidence, preliminary analyses found fewer breast cancers in women in the CEE group, prompting a detailed updated analysis of breast cancer incidence and mammographic reports.

Marcia L. Stefanick, Ph.D., of Stanford University, Stanford, Calif., and colleagues with the WHI study, analyzed the data from the CEE-alone group of the WHI study to determine the effects of CEE on breast cancers and mammographic findings. The study included 10,739 postmenopausal women aged 50 to 79 years with prior hysterectomy who were randomized to CEE or placebo at 40 U.S. clinical centers from 1993 through 1998. Mammography screenings and clinical breast examinations were performed at baseline and annually. All breast cancers diagnosed through February 29, 2004, are included. Participants received a dose of 0.625 mg/d of CEE or an identical-appearing placebo.

In an analyses of all events (n = 237 cases) occurring prior to intervention termination, after an average follow-up of 7.1 years, nonsignificant reductions were observed for invasive breast cancer (20 percent lower rate) and for total breast cancer (18 percent lower rate) in women randomized to CEE, when compared to the placebo group. The annualized rates were 0.28 (104 cases in the CEE group) and 0.34 (133 cases in the placebo group). In further analyses, fewer breast cancers with localized disease were diagnosed
'"/>

Contact: Susan Ipaktchian
650-725-5375
JAMA and Archives Journals
11-Apr-2006


Page: 1 2

Related medicine news :

1. COX inhibitors may weaken protective qualities of estrogen hormone therapy
2. Study describes action of estrogen in protecting bone
3. New path from estrogen to survival in breast cancer cells described
4. High estrogen levels associated with dementia in older men
5. Ultra low-dose estrogen shown safe for post-menopausal women
6. Gabapentin cools hot flashes as well as estrogen
7. Study uncovers significant functional differences of novel estrogen receptor
8. Early estrogen exposure leads to later prostate cancer risk
9. Long-term estrogen therapy linked to breast cancer risk
10. Low estrogen levels in men linked to increased risk for hip fracture
11. Benefit of chemotherapy in breast cancer depends on estrogen-receptor status

Post Your Comments:
(Date:9/2/2015)... ... 03, 2015 , ... The Aspen Clinic (TAC), located in Basalt, ... kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, ... mind-body approach to fitness - we are much more than a gym. Our ...
(Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
(Date:9/2/2015)... , ... September 03, 2015 , ... ... to determine who among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, health ... health care. This year, that process led the magazine to tap the National ...
(Date:9/2/2015)... ... September 02, 2015 , ... Chris Harrison of Harrison’s ... “It was a simple decision, really,” says Chris. “We have a lot of repeat ... the brands that work best for them—so we’ve given them the convenience of ordering ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading ... two leaders who will deliver keynote presentations at the upcoming Digital Healthcare Innovation ... Hotel in Boston. , Larry Renfro, CEO of Optum, will deliver the morning ...
Breaking Medicine News(10 mins):Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3
(Date:9/2/2015)... Sept. 2, 2015 About Neuroendovascular Coil ... to treat an unruptured and ruptured brain aneurysm ... treatment is either known as an endovascular coiling ... coil blocks the blood flow in an aneurysm. ... general anaesthesia by an interventional neuroradiologist using fluoroscopic ...
(Date:9/2/2015)... BOULDER, Colo. , Sept. 2, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Securities Healthcare Conference in Boston.  The public is ... webcast on the Array BioPharma website.Event: Wells Fargo ... , Thursday, September 10, 2015Time:  , 10:20 a.m. ...
(Date:9/2/2015)... Transaction Highlights: ... profitable specialty products , Expands pipeline with ... 11 product applications pending at the FDA, of ... Provides medium and longer term growth potential with ... substances , Adds development expertise in difficult ...
Breaking Medicine Technology:Global Neuroendovascular Coil Market 2015-2019 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6
Cached News: